ATE526037T1 - Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen - Google Patents

Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen

Info

Publication number
ATE526037T1
ATE526037T1 AT04812982T AT04812982T ATE526037T1 AT E526037 T1 ATE526037 T1 AT E526037T1 AT 04812982 T AT04812982 T AT 04812982T AT 04812982 T AT04812982 T AT 04812982T AT E526037 T1 ATE526037 T1 AT E526037T1
Authority
AT
Austria
Prior art keywords
tumor cells
apoptotic
killing
internal antigens
antigens exposed
Prior art date
Application number
AT04812982T
Other languages
English (en)
Inventor
Elizabeth E Evans
Mark J Paris
Deepak M Sahasrabudhe
Ernest S Smith
Maurice Zauderer
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Application granted granted Critical
Publication of ATE526037T1 publication Critical patent/ATE526037T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
AT04812982T 2003-12-04 2004-12-06 Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen ATE526037T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52657203P 2003-12-04 2003-12-04
US53168803P 2003-12-23 2003-12-23
PCT/US2004/040573 WO2005055936A2 (en) 2003-12-04 2004-12-06 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Publications (1)

Publication Number Publication Date
ATE526037T1 true ATE526037T1 (de) 2011-10-15

Family

ID=34681506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812982T ATE526037T1 (de) 2003-12-04 2004-12-06 Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen

Country Status (10)

Country Link
US (2) US20050158323A1 (de)
EP (1) EP1708751B1 (de)
JP (1) JP5042631B2 (de)
CN (1) CN1913921B (de)
AT (1) ATE526037T1 (de)
AU (1) AU2004296184B2 (de)
CA (1) CA2548180C (de)
IL (1) IL176007A (de)
NZ (1) NZ547591A (de)
WO (1) WO2005055936A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522282A (en) * 2000-04-04 2005-03-24 Univ Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CA2588758C (en) * 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
AU2006281980A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
AU2007325520A1 (en) * 2006-10-13 2008-06-05 The Regents Of The University Of California Cancer treatment
BRPI0720219A2 (pt) 2006-12-08 2013-12-24 Univ Iowa State Res Found Inc Genes de planta envolvidos em absorção e metabolismo de nitrato
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
CN108912228B (zh) 2009-05-08 2022-03-15 瓦西尼斯公司 抗-cd100抗体和其使用方法
AU2010300380B2 (en) * 2009-10-02 2016-06-09 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
US8980284B2 (en) * 2010-01-25 2015-03-17 New York University Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
RS59253B1 (sr) 2011-05-08 2019-10-31 Legochem Biosciences Inc Konjugati aktivnog agensa proteina i postupak za njihovo dobijanje
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
WO2014069682A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069681A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
MX2015017485A (es) 2013-06-25 2016-03-31 Vaccinex Inc Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
CA2969463A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
EP3350595B1 (de) * 2015-09-14 2021-08-04 Leukemia Therapeutics, LLC Identifizierung neuartiger diagnostika und therapeutika durch modulation von rhoh
RU2759846C2 (ru) 2016-04-22 2021-11-18 Вэксинекс, Инк. Дисплей интегрального мембранного белка на внеклеточных оболочечных вирионах поксвируса
US10994033B2 (en) * 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
JPS57154232A (en) * 1981-02-18 1982-09-24 Konishiroku Photo Ind Co Ltd Photosensitive silver halide emulsion
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5489425A (en) * 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
ZA894792B (en) * 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5756065A (en) * 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
BR8907507A (pt) * 1988-06-24 1991-06-11 Dow Chemical Co Quelante bifuncional macrociclico,seus complexos e seus conjugados com anticorpos
US5274119A (en) * 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) * 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5808003A (en) * 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5413923A (en) * 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) * 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233750D1 (de) * 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE69214709T2 (de) * 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
US5625425A (en) * 1991-08-28 1997-04-29 Kranhouse; Jon Diving mask with lenses and method of fabricating the same
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK1024191T3 (da) * 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5428139A (en) * 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
CA2141602A1 (en) * 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5441050A (en) * 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5516717A (en) * 1995-04-19 1996-05-14 United Microelectronics Corporation Method for manufacturing electrostatic discharge devices
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US5994560A (en) * 1996-08-29 1999-11-30 Hoechst Celanese Corp. Resolution of racemic mixtures using polymers containing chiral units
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5958660A (en) * 1997-12-31 1999-09-28 Eastman Kodak Company Hydrophilic colloid composition
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
NZ522282A (en) * 2000-04-04 2005-03-24 Univ Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2001255326B2 (en) * 2000-04-12 2005-12-15 University Of Rochester Targeted vaccine delivery systems
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CN1306272C (zh) * 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
CN1604966A (zh) * 2001-10-15 2005-04-06 免疫医疗公司 直接靶定的结合蛋白
NZ537579A (en) * 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Also Published As

Publication number Publication date
AU2004296184B2 (en) 2010-12-16
CN1913921A (zh) 2007-02-14
JP5042631B2 (ja) 2012-10-03
CA2548180C (en) 2014-02-04
AU2004296184A1 (en) 2005-06-23
EP1708751A2 (de) 2006-10-11
US20050158323A1 (en) 2005-07-21
CN1913921B (zh) 2012-02-22
CA2548180A1 (en) 2005-06-23
EP1708751B1 (de) 2011-09-28
US20090081210A1 (en) 2009-03-26
WO2005055936A3 (en) 2005-11-03
EP1708751A4 (de) 2007-11-07
WO2005055936A2 (en) 2005-06-23
NZ547591A (en) 2009-11-27
IL176007A (en) 2012-03-29
JP2007515165A (ja) 2007-06-14
IL176007A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
NO20060843L (no) RG1-antistoffer og anvendelser derav
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
ATE443260T1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
ATE291738T1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
WO2005114216A3 (en) Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU2018256601A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
EA202090431A1 (ru) Мутеины интерлейкина-21 и способы лечения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties